European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A Hochhaus, M Baccarani, RT Silver, C Schiffer… - Leukemia, 2020 - nature.com
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Abstract The World Health Organization (WHO) classification of tumors of the hematopoietic
and lymphoid tissues was last updated in 2008. Since then, there have been numerous …
and lymphoid tissues was last updated in 2008. Since then, there have been numerous …
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
D Rea, MJ Mauro, C Boquimpani… - Blood, The Journal …, 2021 - ashpublications.org
Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to≥ 2
tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of …
tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of …
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
HM Kantarjian, TP Hughes, RA Larson, DW Kim… - Leukemia, 2021 - nature.com
In the ENESTnd study, with≥ 10 years follow-up in patients with newly diagnosed chronic
myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative …
myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative …
Long-term outcomes of imatinib treatment for chronic myeloid leukemia
A Hochhaus, RA Larson, F Guilhot… - … England Journal of …, 2017 - Mass Medical Soc
Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
A Hochhaus, D Réa, C Boquimpani, Y Minami… - Leukemia, 2023 - nature.com
Asciminib, the first BCR:: ABL1 inhibitor that S pecifically T argets the A BL M yristoyl P ocket
(STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome …
(STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome …
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non …
S Saussele, J Richter, J Guilhot, FX Gruber… - The Lancet …, 2018 - thelancet.com
Summary Background Tyrosine kinase inhibitors (TKIs) have improved the survival of
patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a …
patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a …
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2018 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1
J Schoepfer, W Jahnke, G Berellini, S Buonamici… - 2018 - ACS Publications
Chronic myelogenous leukemia (CML) arises from the constitutive activity of the BCR-ABL1
oncoprotein. Tyrosine kinase inhibitors (TKIs) that target the ATP-binding site have …
oncoprotein. Tyrosine kinase inhibitors (TKIs) that target the ATP-binding site have …
Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial
JE Cortes, C Gambacorti-Passerini… - Journal of Clinical …, 2018 - ascopubs.org
Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with
Philadelphia chromosome–positive chronic myeloid leukemia (CML) resistant and/or …
Philadelphia chromosome–positive chronic myeloid leukemia (CML) resistant and/or …